Effect and Safety of Kangfuyan Capsules () for Relieving Chronic Pelvic Pain: A Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Clinical Trial / 中国结合医学杂志

OBJECTIVE@#To evaluate the effect and safety of Kangfuyan Capsules () for treating pelvic inflammatory disease (PID) in patients with chronic pelvic pain (CPP) in a multicenter, randomized, controlled, double-blind, parallel-group clinical trial.@*METHODS@#Totally, 240 PID patients with CPP were randomized into 2 groups using a computer generated random number at a 1:1 ratio from 10 hospitals in China between September 2014 and November 2015. Patients received either oral Kangfuyan Capsules or Gongyanping Capsules (, control); the regimen for both groups comprised 4 capsules (3 times daily) for 12 weeks, with follow-up visit 4 weeks after treatment. The visual analogue scale (VAS) scores, clinical responses, remarkable cure rates for each symptom, and quality of life scores were assessed at baseline, and after 1, 2, and 3 months. Adverse events were also recorded.@*RESULTS@#The VAS scores were significantly lower (P<0.05), whereas the clinical responses, remarkable cure rates for lower abdominal pain, uterine tenderness, adnexal mass, and adnexal tenderness, and Health-related quality of life (EQ-5D) scores were higher in the Kangfuyan group than in the control group at 3 months (P<0.05). Common treatment-related adverse events included high hepatic enzyme levels, reduced hemoglobin levels, and elevated platelet counts, although all the adverse events were either mild or moderate in severity.@*CONCLUSION@#Compared with Gongyanping therapy, Kangfuyan therapy yielded markedly better analgesia effects for CPP caused by PID, with obvious long-term efficacy and good safety. (Registration No. ChiCTR190022732).

Kangfuyan capsule combined with antibiotics for pelvic inflammatory diseases:a Meta-analysis / 中国实用妇科与产科杂志

OBJECTIVE: To evaluate the efficacy and safety of Kangfuyan capsule combined with antibiotics in the treatment of pelvic inflammatory diseases.METHODS: The CNKI,WANFANG,VIP,CBM,Pubmed,Embase and The Cochrane Library were searched from their date of foundation to August 1,2018.The randomized controlled trial were included on the treatment for pelvic inflammatory diseases by Kangfuyan capsules with antibiotics or by antibiotics alone.Meta-analysis was conducted using RevMan5.3 software.RESULTS: Totally 20 reports(2820 subjects)were included.The clinal of cure rate,pain relief,pelvic signs relief,pelvic effusion reduction,decrease in recurrence rate had statistical difference between two groups(P0.05).CONCLUSION: Kangfuyan capsule combined with antibiotics in treating pelvic inflammatory disease can improve clinical efficacy,reduce the occurrence of sequelae of pelvic inflammatory disease,without increasing adverse reactions.A large quantity of samples and long-term clinical studies need to be conducted to confirm the effects.

Clinical effect of cefoxitin sodium combined with Kangfuyan capsules in the treatment of pelvic inflammatory disease and its influence on inflammatory cytokines / 中国基层医药

Objective To investigate the clinical effect of cefoxitin sodium combined with Kangfuyan capsules in the treatment of pelvic inflammatory disease and its influence on inflammatory cytokines .Methods According to the random number table method ,450 cases with chronic pelvic inflammatory disease were divided into the observation group and the control group ,225 cases in each group .The observation group was given cefoxitin sodium combined with Kangfuyan capsules treatment ,the control group received cefoxitin sodium therapy .The treatment effect and the changes of inflammatory cytokines before and after treatment were compared between the two groups .Results The total effective rate(93.3％vs.86.7％) and the cure rate(66.7％vs.53.5％) of the observation group were signif-icantly higher than those of the control group ,the differences were statistically significant (χ2 =8.333,5.556,all P<0.05).After treatment,the TNF-alpha,IL-6 and CRP levels in the two groups were significantly decreased ,which of the observation group were better than those of the control group [(43.7 ±18.2)ng/L vs.(53.2 ±21.6)ng/L, (323.8 ±124.6)ng/L vs.(399.5 ±141.3)ng/L,(9.7 ±3.5)mg/L vs.(13.4 ±5.9)mg/L],the differences were statistically significant(t=7.865,5.783,4.517,all P<0.05).Conclusion Cefoxitin sodium combined with Kang-fuyan capsule in the treatment of chronic pelvic inflammatory disease ,can significantly improve the treatment effect , improve the level of inflammatory cytokines .